Krka, D. D., Novo Mesto · LJSE:KRKG
Krka, D. D., Novo Mesto — H1 2025 Earnings Presentation
19 slides from Krka, D. D., Novo Mesto's earnings presentation, Jul 24, 2025
Slide 1: Krka Group Business Performance H1 2025 Presentation
Webcast Krka Group Business Performance H1 2025 Presentation 24 July 2025 www.krka.biz
Slide 2: H1 2025 Performance highlights
Krka Group Business Performance H1 2025 Performance highlights SALES 5Y CAGR: 5.5% ✓ Record H1 2025 sales: €1,048.5m; +6% yoy; volume growth: +4% yoy In 985 1,049 EUR 807 857 920 ✓ EBITDA margin: 28.9%; EBIT margin: 24.5% million 1-6 21 1-6 22 1-6 23 1-6 24 1-6 25 ✓ Record H1 2025 net profit: €246.7
Slide 3: Krka Group Sales by Regions
Krka Group Sales by Regions Continuation of robust sales dynamics H1 2025 sales: EUR 1,045.8m of goods and Top 5 markets Russian Federation +12% 168 173 180 195 219 services (+7% yoy; EUR +64.9m) In EUR million 1-6/2021 1-6/2022 1-6/2023 1-6/2024 1-6/2025 Overseas Markets Slovenia EUR 33.2m Poland;
Slide 4: Sales by country
Sales by country Geographically well-diversified sales activities ✓ Top 10 countries by sales €10m represent 60% of Krka group (+10%) €219m sales. (+12%) ✓ Leading provider of medicines in Scandinavian countries €10m €27m (+4%) (+0%) Slovenian market with 7.3% market share. €19m (+11%) ✓ Leading pro
Slide 5: Broad Product Portfolio
Broad Product Portfolio Rx remain most important product group with EUR +55m increase yoy Health-resort & tourist services +12% Majority of sales for Animal health products EUR 26.2m; companion animals EUR 63.4m; (EUR +3m) +5% Prescription (EUR +3m) pharmaceuticals (Rx) +7% EUR 878.3m; (EUR +55m) No
Slide 6: Research and Development
Research and Development Committed to continuous development of innovative branded generic products 11 new MA for products & over 500 MA procedures finalised €95m R&D expenses H1 2025: ✓ Dagraduo* (sitagliptin, dapagliflozin) diabetes New product share ✓ Mexdagry & Lynxaram for reliable glycaemic co
Slide 7: Krka's Innovative Medicines
Krka’s Innovative Medicines Innovative branded generic producer with own R&D ADVANCED UNIQUE STATE-OF-THE-ART UNIQUE PHARMACEUTICAL SINGLE PILL EQUIPMENT Delivering the most demanding FORMULATIONS Great possibility of STRENGTHS Tailoring the COMBINATIONS Synergistic action & >150 projects in terms o
Slide 8: Investments
Investments Increasing the resilience and flexibility of our business model Notol 2 – Slovenia CAPEX H1 2025: €41m; FY 2025 plan: €150m Predominantly increasing and technologically upgrading production facilities and capacities for development and quality management. Production – vertical process Pa
Slide 9: Consolidated Income Statement
Consolidated Income Statement Maintaining high profitability EUR thousand H1 2025 (%) H1 2024 (%) YoY +6% 795,688 Revenue 1,048,541 100 985,418 100 6% 750,965 Costs of goods sold 441,156 418,540 5% Gross profit 607,385 58 566,878 58 7% 441,156 418,540 Other operating income 4,124 0 3,222 0 28% 42.1%
Slide 10: FX Impact
FX Impact Significant appreciation of RUB in H1 2025 EUR/RUB FX rate (2020 – H1 2025) 60 160 The Krka Group's financial Neto NFIfinančni izid profit, which includes 140 30 EURRUB +42.4m EUR currency differences, interest +51.9m EUR +29,6m EUR 120 income and expenses, the EUR million EURRUB (H1 2024)
Slide 11: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position Strong financial position without leverage burden EUR thousand 30.6.2025 (%) 31.12.2024 (%) change change % ASSETS 3,145,164 100 2,849,021 100 296,143 10% Non-current assets 1,050,070 33 1,022,901 36 27,169 3% Current assets 2,095,094 67 1,826,120 64 268,
Slide 12: Krka Group Operating Results
Krka Group Operating Results Maintaining high profitability Profitability Margins development 70% EUR million H1 2025 H1 2024 yoy 57% 57% 57% 57% 57.9% 60% Gross profit 607.4 566.9 7% 50% Gross profit margin 57.9% 57.5% Average EBITDA margin: 29.2% EBITDA 303.3 283.7 7% 40% EBITDA margin 28.9% 28.8%
Slide 13: Performance Indicators
Performance Indicators Maintaining long-term momentum Revenue in € million EBITDA in € million 2,500 600 504 520 539 2000 464 488 1806 1910 500 2,000 1717 Q2 2025 1565 400 1,500 5y average (2020-2024) Q1 2025 300 EBITDA margin: 29.2% 1,000 200 Q4 2024 500 5Y CAGR 5.1% H1 2025 100 5Y CAGR 6.2% Q3 202
Slide 14: Dividend Policy and Share Buyback
Dividend Policy and Share Buyback Management committed to stable capital allocation DPS and dividend yield* for the business year Treasury shares as of total Dividend approved by AGM Repurchased €24m of treasury shares in H1 2025 9.00 8% 8% 6.9% 8.00 7% 6.4% 10Y CAGR 14.1% 7.00 5.9% 6% 6% 5.4% 5.1%
Slide 15: Share Information and Shareholder Structure
Share Information and Shareholder Structure Stable shareholder structure (KRKG SV) Average daily turnover and stock price YTD Shareholder structure as of 30 June 2025 1,400 1244 200 1,200 1,000 175 18.6% EUR thousand 759 800 653 667 150 600 519 41.7% 125 6.9% 400 100 200 75 0 EUR 2021 2022 2023 2024
Slide 16: ESG Governance of Krka Group
ESG Governance of Krka Group CSRD/ESRS reporting requirements implementation Material ESG Topic Groups Key Activities ✓ Implementation of CSRD/ESRS ACCESSIBLE HEALTHCARE requirements in sustainability reporting. ✓ New audited Sustainability statement PRODUCT QUALITY & PATIENT SAFETY published within
Slide 17: Guidance for 2025
Guidance for 2025 In line with strategic goals Sales Net Income (EUR mio) (EUR mio) 2025 Guidance 2,000+ 365 1,910 356 Sales: EUR 2,000+ million 1,850 310 Net Income: EUR 365 million 2024 Initial 2024 2025 2024 Initial 2024 2025 GUIDANCE RAISED in January 2025 guidance guidance guidance upgraded gui
Slide 18: Living a healthy life.
Living a healthy life.
Slide 19: Disclaimer
Disclaimer The information, statements or data contained in this presentation has been prepared by Krka, tovarna zdravil, d. d., Novo mesto (hereinafter: the Company) and has been prepared solely for the purpose of informative presentation of the Company business operations. The presentation is not
Krka, d. d., Novo mesto — H1 2025 Earnings Presentation on 6ix